Aandelen in “Fabricage van farmaceutische preparaten”

Aandeel Datum Koers Evolutie
vlag Qualigen Therapeutics Inc 30/04 3,580 USD
+2,87% 		+2,87%

Nieuws over “Fabricage van farmaceutische preparaten”

07:01 · Beursagenda: Belgische bedrijven · Trends (€)

Beursagenda: Belgische bedrijven

07:01 · Beursagenda: Belgische bedrijven · Trends (€)

(ABM FN) Hieronder volgen de belangrijkste items op de financiële agenda voor België tot en met donderdag 8 mei 2025:DONDERDAG 1 MEI 202509:00 Euronext Brussel gesloten op Dag van de ArbeidVRIJDAG 2 MEI 202509:00 WDP - Ex-dividend00:00...

30/04 · Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference · Persbericht

30/04 · Press Release: Annual General Meeting of April 30, 2025 · Persbericht

30/04 · Beursagenda: Belgische bedrijven · Trends (€)

(ABM FN) Hieronder volgen de belangrijkste items op de financiële agenda voor België tot en met donderdag 8 mei 2025:DONDERDAG 1 MEI 202509:00 Euronext Brussel gesloten op Dag van de ArbeidVRIJDAG 2 MEI 202509:00 WDP - Ex-dividend00:00...

30/04 · Perrigo Announces Quarterly Dividend · Persbericht

30/04 · Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG) · Persbericht

30/04 · Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting · Persbericht

30/04 · Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial · Persbericht

30/04 · Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader · Persbericht

30/04 · New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) · Persbericht

30/04 · Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG · Persbericht

30/04 · AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update · Persbericht

30/04 · Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery · Persbericht

29/04 · CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE · Persbericht

29/04 · Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information · Persbericht

29/04 · Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update · Persbericht

29/04 · Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy · Persbericht

29/04 · RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA) · Persbericht

29/04 · Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting · Persbericht

29/04 · Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race · Persbericht

Mijn selecties